BOSTON (MedPage Today) -- Two investigational drugs targeting the hepatitis C virus (HCV) protease enzyme helped patients clear the virus with once-daily dosing, in contrast with the three-times-per-day schedule needed for similar drugs in development.
protease enzymeAASLD: Once-Daily HCV Protease Inhibitors Show Early Promise (CM...MedPage Today Infectious Disease Tue, 11/03/2009 - 10:26
|
